CompletedPhase 4

Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI

South Korea108 participantsStarted 2022-12-01

Plain-language summary

Investigators aimed to evaluate efficacy and safety of early Initiation of evolocumab and combination lipid-lowering agent (statin + Ezetimibe) on lipid profiles changes in patients with ACS undergoing PCI

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Over 19 years old
✓. Patients who agreed to the research protocol and clinical follow-up survey plan, decided to participate in this study voluntarily, and gave written consent to the informed consent form.
✓. Patients who underwent percutaneous coronary stenting for acute coronary syndrome

Exclusion criteria

✕. Patients who have previously taken statins,
✕. Patients with active liver disease or patients with three times or more increase in AST or ALT
✕. If you have an allergic or hypersensitivity reaction to Evorucumab, statin, or Ezetimib,
✕. Pregnant women, lactating women, or women of childbearing age who plan to become pregnant during this study
✕. The remaining life expectancy is expected to be less than a year.
✕. Subjects who visited the hospital due to psychogenic shock and are expected to be less likely to survive by medical judgment
✕. Subjects participating in a randomized clinical trial of medical devices/pharmaceuticals

What they're measuring

Percent change in LDL level (%)

Timeframe: Baseline, 2 weeks later

Trial details

NCT IDNCT05661552

SponsorYonsei University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-02-05

View on ClinicalTrials.gov More Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia trials